VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
2794
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
503
Interactions with Platform & by Email
PARTICIPANTS
84
Unique # Participated
VALIDATIONS
38
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JULY 2020
TABLES
99
PAGES
171
EDITION
9
PRICE
USD $4950
It Pays to Understand the Dynamics of Competition in Your Business Ecosystem.
Who Are Your Competitors in the Chronic Myelogenous Leukemia Treatment Market?
Amid the COVID-19 crisis, the global market for Chronic Myelogenous Leukemia Treatment estimated at US$5.3 Billion in the year 2020, is projected to reach a revised size of US$7.6 Billion by 2027, growing at aCAGR of 5.3% over the period 2020-2027. Disease Specific Treatment, one of the segments analyzed in the report, is projected to record 5.9% CAGR and reach US$2.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Symptomatic Treatment segment is readjusted to a revised 5% CAGR for the next 7-year period.
The Chronic Myelogenous Leukemia Treatment market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.We bring years of research experience to this 9th edition of our report. The 171-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Bio-Path Holdings, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Incyte Corporation; Novartis AG; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.
» Drug Type (Branded, Generic) » Treatment Type (Disease Specific Treatment, Symptomatic Treatment)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Global Competitor Market Shares |
| Chronic Myelogenous Leukemia Treatment Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| Chronic Myelogenous Leukemia Treatment Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 |
| Chronic Myelogenous Leukemia Treatment Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Branded (Drug Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 |
| Branded (Drug Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 |
| Branded (Drug Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Generic (Drug Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 |
| Generic (Drug Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 |
| Generic (Drug Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 |
| Disease Specific Treatment (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 |
| Disease Specific Treatment (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 |
| Disease Specific Treatment (Treatment Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Symptomatic Treatment (Treatment Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 |
| Symptomatic Treatment (Treatment Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 |
| Symptomatic Treatment (Treatment Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| UNITED STATES |
| Market Facts & Figures |
| US Chronic Myelogenous Leukemia Treatment Market Share (in %) by Company: 2019 & 2025 |
| United States Chronic Myelogenous Leukemia Treatment Market Estimates and Projections in US$ Million by Drug Type: 2018 to 2025 |
| Chronic Myelogenous Leukemia Treatment Market in the United States by Drug Type: A Historic Review in US$ Million for 2009-2017 |
| United States Chronic Myelogenous Leukemia Treatment Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| United States Chronic Myelogenous Leukemia Treatment Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 |
| Chronic Myelogenous Leukemia Treatment Market in the United States by Treatment Type: A Historic Review in US$ Million for 2009-2017 |
| United States Chronic Myelogenous Leukemia Treatment Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 |
| CANADA |
| Canadian Chronic Myelogenous Leukemia Treatment Market Estimates and Forecasts in US$ Million by Drug Type: 2018 to 2025 |
| Canadian Chronic Myelogenous Leukemia Treatment Historic Market Review by Drug Type in US$ Million: 2009-2017 |
| Chronic Myelogenous Leukemia Treatment Market in Canada: Percentage Share Breakdown of Sales by Drug Type for 2009, 2019, and 2025 |
| Canadian Chronic Myelogenous Leukemia Treatment Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 |
| Canadian Chronic Myelogenous Leukemia Treatment Historic Market Review by Treatment Type in US$ Million: 2009-2017 |
| Chronic Myelogenous Leukemia Treatment Market in Canada: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 |
| JAPAN |
| Japanese Market for Chronic Myelogenous Leukemia Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Type for the Period 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Market in Japan: Historic Sales Analysis in US$ Million by Drug Type for the Period 2009-2017 |
| Japanese Chronic Myelogenous Leukemia Treatment Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| Japanese Market for Chronic Myelogenous Leukemia Treatment: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Market in Japan: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 |
| Japanese Chronic Myelogenous Leukemia Treatment Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 |
| CHINA |
| Chinese Chronic Myelogenous Leukemia Treatment Market Growth Prospects in US$ Million by Drug Type for the Period 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Historic Market Analysis in China in US$ Million by Drug Type: 2009-2017 |
| Chinese Chronic Myelogenous Leukemia Treatment Market by Drug Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Chinese Chronic Myelogenous Leukemia Treatment Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Historic Market Analysis in China in US$ Million by Treatment Type: 2009-2017 |
| Chinese Chronic Myelogenous Leukemia Treatment Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| EUROPE |
| Market Facts & Figures |
| European Chronic Myelogenous Leukemia Treatment Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
| European Chronic Myelogenous Leukemia Treatment Market Demand Scenario in US$ Million by Region/Country: 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 |
| European Chronic Myelogenous Leukemia Treatment Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Chronic Myelogenous Leukemia Treatment Market Estimates and Forecasts in US$ Million by Drug Type: 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Market in Europe in US$ Million by Drug Type: A Historic Review for the Period 2009-2017 |
| European Chronic Myelogenous Leukemia Treatment Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| European Chronic Myelogenous Leukemia Treatment Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Market in Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 |
| European Chronic Myelogenous Leukemia Treatment Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 |
| FRANCE |
| Chronic Myelogenous Leukemia Treatment Market in France by Drug Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
| French Chronic Myelogenous Leukemia Treatment Historic Market Scenario in US$ Million by Drug Type: 2009-2017 |
| French Chronic Myelogenous Leukemia Treatment Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| Chronic Myelogenous Leukemia Treatment Market in France by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
| French Chronic Myelogenous Leukemia Treatment Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 |
| French Chronic Myelogenous Leukemia Treatment Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 |
| GERMANY |
| Chronic Myelogenous Leukemia Treatment Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Type for the Period 2018-2025 |
| German Chronic Myelogenous Leukemia Treatment Historic Market Analysis in US$ Million by Drug Type: 2009-2017 |
| German Chronic Myelogenous Leukemia Treatment Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| Chronic Myelogenous Leukemia Treatment Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 |
| German Chronic Myelogenous Leukemia Treatment Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 |
| German Chronic Myelogenous Leukemia Treatment Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 |
| ITALY |
| Italian Chronic Myelogenous Leukemia Treatment Market Growth Prospects in US$ Million by Drug Type for the Period 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Historic Market Analysis in Italy in US$ Million by Drug Type: 2009-2017 |
| Italian Chronic Myelogenous Leukemia Treatment Market by Drug Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Italian Chronic Myelogenous Leukemia Treatment Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Historic Market Analysis in Italy in US$ Million by Treatment Type: 2009-2017 |
| Italian Chronic Myelogenous Leukemia Treatment Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| UNITED KINGDOM |
| United Kingdom Market for Chronic Myelogenous Leukemia Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Type for the Period 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Type for the Period 2009-2017 |
| United Kingdom Chronic Myelogenous Leukemia Treatment Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| United Kingdom Market for Chronic Myelogenous Leukemia Treatment: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Market in the United Kingdom: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 |
| United Kingdom Chronic Myelogenous Leukemia Treatment Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 |
| REST OF EUROPE |
| Rest of Europe Chronic Myelogenous Leukemia Treatment Market Estimates and Forecasts in US$ Million by Drug Type: 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Market in Rest of Europe in US$ Million by Drug Type: A Historic Review for the Period 2009-2017 |
| Rest of Europe Chronic Myelogenous Leukemia Treatment Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| Rest of Europe Chronic Myelogenous Leukemia Treatment Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 |
| Chronic Myelogenous Leukemia Treatment Market in Rest of Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 |
| Rest of Europe Chronic Myelogenous Leukemia Treatment Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 |
| ASIA-PACIFIC |
| Chronic Myelogenous Leukemia Treatment Market in Asia-Pacific by Drug Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Asia-Pacific Chronic Myelogenous Leukemia Treatment Historic Market Scenario in US$ Million by Drug Type: 2009-2017 |
| Asia-Pacific Chronic Myelogenous Leukemia Treatment Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| Chronic Myelogenous Leukemia Treatment Market in Asia-Pacific by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Asia-Pacific Chronic Myelogenous Leukemia Treatment Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 |
| Asia-Pacific Chronic Myelogenous Leukemia Treatment Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 |
| REST OF WORLD |
| Rest of World Chronic Myelogenous Leukemia Treatment Market Estimates and Forecasts in US$ Million by Drug Type: 2018 to 2025 |
| Rest of World Chronic Myelogenous Leukemia Treatment Historic Market Review by Drug Type in US$ Million: 2009-2017 |
| Chronic Myelogenous Leukemia Treatment Market in Rest of World: Percentage Share Breakdown of Sales by Drug Type for 2009, 2019, and 2025 |
| Rest of World Chronic Myelogenous Leukemia Treatment Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 |
| Rest of World Chronic Myelogenous Leukemia Treatment Historic Market Review by Treatment Type in US$ Million: 2009-2017 |
| Chronic Myelogenous Leukemia Treatment Market in Rest of World: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 4 Click here to request a full table of contents and more details on this project. |
| V. CURATED RESEARCH |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com